European Medicines Agengy released a report which shows that there are 6 biosimilar applications to the Agency in the first half of 2012.
The report from the Executive Director to the Management Board which covers the first six months of the year, provides an overview of the Agency’s progress in implementing the work programme 2012. The reports presents information about the performance of the evaluation activities, the implementation of objectives and reaching set performance targets measured by indicators.
Although the number of generic applications is almost the half of the prvious years’ first half, the biosimilar applications are increasing. In the first half of 2011, there were 21 generic product applications but this year, the number is reduced to 11. But although there were none biosimilar applications in the first half of 2011, this year, there are six similar biological product applications to the Europe’s watchdog.
This important detail shows us that, not only Celltrion’s infliximab, but also there may be more biosimilars on the European market in the near future.
If you want to get more information about EMA’s first half of this year, you can reach the full report from here.